晨光生物(300138.SZ)擬向邯鄲晨光增資1.5億元
格隆匯12月26日丨晨光生物(300138.SZ)發佈公吿,公司第四屆董事會第三十七次會議審議通過議案,公司全資子公司晨光生物科技集團邯鄲有限公司(簡稱“邯鄲晨光”),註冊資本5000萬元,位於河北省邯鄲市開發區。該子公司目前承擔了公司“三個中心”(研發中心、中試中心、檢測中心)、保健食品業務、中藥產業研究院及相關配套設施建設。
為滿足其經營規模發展需要,改善其資產負債結構,支持新業務開展,公司擬使用自有資金向邯鄲晨光增資1.5億元。本次增資完成後,邯鄲晨光註冊資本將增加至2億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.